Seeking Alpha

Navidea Biopharmaceuticals (NAVB) enrolls the first subject in a Phase III trial for its NAV4694...

Navidea Biopharmaceuticals (NAVB) enrolls the first subject in a Phase III trial for its NAV4694 imaging agent, which is designed to identify whether patients have Alzheimer's disease, which can only be confirmed during autopsy. Yesterday, Navidea secured tens of millions of dollars in financing. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector